NIMG-37. DELAYED PSEUDOPROGRESSION IN TWO PATIENTS UNDERGOING TTFIELDS TREATMENT FOR NEWLY DIAGNOSED GLIOBLASTOMA

PURPOSE: Tumor treatment fields (TTFields) are approved by the FDA for newly diagnosed as well as recurrent glioblastoma (GBM). TTFields have been shown to extend survival by 4.9 months in newly diagnosed GBM, and a landmark overall survival rate of 13% at 5 years. However, the specific effects rema...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Neuro Oncol
Huvudupphovsmän: Lowman, Allison, Hurrell, Sarah, Bobholz, Samuel, Connelly, Jennifer, Cochran, Elizabeth, Mueller, Wade, McGarry, Sean, Brehler, Michael, LaViolette, Peter
Materialtyp: Artigo
Språk:Inglês
Publicerad: Oxford University Press 2020
Ämnen:
Neuroimaging
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651686/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.650
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk